10:30pm (EST)
1. Market Summary
2. DuPont (DD) – Growing Higher
3. Exelixis (EXEL) – Time To Excel
4. Earnings
5. Weekly Wrap Portfolio Update
6. Week Ahead
= = = = = = = = = = = = = = =
1. Market Summary
The bears woke up on a holiday shortened week and put a stop to a 3-week long rally that saw the bulls on the cusp of another breakout. We have been expecting a slight pullback but we thought the downturn would come during February options expiration week which was the prior week. However, with rising tensions in the Middle East and North Africa escalating, and oil surging 15%, the bulls were facing an uphill battle.
The Dow gained 62 points, or 0.5%, on Friday and closed at 12,130. For the week, the index fell 260 points, or 2.1%, and saw its 3-week winning streak come to an end. We had a feeling when the blue-chips reached our 12,300-12,350 target that a pause was coming but the good news is that the bulls held support. The Dow was able to hold 12,200 on Tuesday and 12,000 on Wednesday before finishing this week right between our downside targets. There is further support at 11,800 and then 11,600-11,500.
The S&P 500 added 14 points, or 1.1%, and settled at 1,319. For the week, the index dropped 23 points, or 1.7%. It was the biggest decline since mid-November but we were encouraged by the close above 1,300 each day. This area will continue to act as short-term support with 1,275 and 1,250 providing additional layers of backup.
The Nasdaq advanced 43 points, or 1.6%, on Friday to finish at 2,781. For the week, the index declined 53 points, or 1.9%. On Tuesday, our first line of support held which was the 2,750 level. On Wednesday and Thursday 2,700 came into play but held. There is additional support at 2,650-2,600.
We were encouraged by Friday’s action but we remain a little cautious until some of the world’s tensions ease up. While we doubt the current bull market rally has officially ended, we could be setting up for a test lower or at least a trading range for a few weeks. We would like to see the bulls make a push back to resistance then hold but it will all depend on the price of oil. If oil stays under $100 then we should see some stabilization in the market. If it climbs higher then we can almost expect the next wave of support to be tested.
= = = = = = = = = = = = = = =
2. DuPont (DD) – Growing Higher
The recent pullback in DuPont’s (DD, $54.07, up $1.03) stock presents an excellent buying opportunity for investors. However, they are faced with the question, is it still a good buy? Based on fundamentals and technicals, yes, the company is still a good buy despite risks, most notably raw material prices.
DD is a global chemicals giant with operations in more than 90 countries. Fouth-quarter consolidated net sales were $7.4 billion.
EMEA = Europe, Middle East, and Africa
The U.S. supplies a big chunk of their sales (30%), so any weakness in the U.S. will hurt sales to some extent. In their most recent conference call the CEO mentioned that they expect a GDP growth of 3-4%, along with 10% growth in the auto industry. He also believes the agricultural business will stay strong, saying that despite rising prices to compensate rising raw material costs, farmers will pay whatever they can to keep their yields high. The company makes pesticides and seeds, competing with Monsanto (MON, $72.21, up $1.67).
Dupont’s business has paid off big in China and Taiwan, where full-year sales grew 50%. Key point here is that China has recently surpassed the U.S. as the largest auto market.
Corn, soybean, and other agricultural produce imports by China have kept demand for the company’s agricultural products high. China is expecting to increase their corn imports by sevenfold. Expect U.S. farmers to increase demand on everything from seeds to pesticides.
A somewhat surprising driver of sales growth in China has been Titanium dioxide (TiO2). The compound is used mainly in paint. Currently, there is a short squeeze in TiO2, and this is expected to last for another three to five years. This is good news for Dupont, the largest maker of TiO2 in the world.
While full year sales in China and Taiwan were $3.3 billion, sales in India were only $678 million. This leaves plenty of room for the company to grow. India is projected to become the 2nd largest auto market in the world, surpassing the U.S. Indian sales grew 40% last year.
Another promising area where the company is active is biofuels. Some analysts predict this area will grow from a $50 billion industry today to a $75 billion industry by 2015. Dupont, through its joint venture with BP, researches non-food based ethanol and the production of butanol. The biomaterials segment makes renewable monomers and polymers. As housing revives, look for chemical demand to pick up.
Meanwhile, mergers and acquisitions remain hot as chemical companies are looking for ways to cut costs. These two forces should keep the stock from falling over the long term. Specifically, Dupont’s recent acquisition of biofuel and food enzyme maker Danisco for $5.8 billion will lower earnings in the short run but raise earnings in the long run. Using CF Industries (CF, $$140.04, up $6.02) acquisition of Terra Industries as an example, earnings will likely jump in 6-12 months from now as the company starts to reap the benefits of the acquisition.
Since Dupont doesn’t report earnings until late April, analysts’ downgrades are the biggest risk going forward. So let’s check out the earnings estimates to see if there could be a possible downgrade.
Consensus:
Earnings: $1.36
Revenue: $9.22B
The chart below shows its earnings history. Earnings per share are non-GAAP.
|
Revenue – Quarterly Results (in $Billions) |
Earnings Per Share – Quarterly Results |
||||||
|
|
2010 |
2009 |
2008 |
|
2010 |
2009 |
2008 |
|
1st Qrt |
8.844 |
7.270 |
8.770 |
1st Qrt |
1.24 |
0.54 |
1.31 |
|
2nd Qrt |
9.080 |
7.088 |
9.279 |
2nd Qrt |
1.17 |
0.61 |
1.11 |
|
3rd Qrt |
7.067 |
6.156 |
7.717 |
3rd Qrt |
0.40 |
0.45 |
0.56 |
|
4th Qrt |
7.742 |
6.814 |
6.070 |
4th Qrt |
0.50 |
0.44 |
-0.28 |
The chart below shows calculations for the growth from prior quarters.
|
Revenue Difference – Quarter-over-quarter |
EPS Difference – Quarter-over-quarter |
||||||
|
|
2010 |
2009 |
2008 |
|
2010 |
2009 |
2008 |
|
1st to 2nd |
0.230 |
-0.182 |
0.509 |
1st to 2nd |
-0.07 |
0.07 |
-0.20 |
|
2nd to 3rd |
-2.013 |
-0.932 |
-1.562 |
2nd to 3rd |
-0.77 |
-0.16 |
-0.55 |
|
3rd to 4th |
0.675 |
0.658 |
-1.647 |
3rd to 4th |
0.10 |
-0.01 |
-0.84 |
|
4th to 1st |
— |
2.030 |
1.200 |
4th to 1st |
— |
0.80 |
0.82 |
This chart predicts 1st quarter revenue of $9.772 billion ($7.742 + $2.030), greater than the $9.22 billion estimate. Both 1st to 2nd quarter revenue difference and 3rd to 4th quarter revenue difference increased from 2009 to 2010. 4th to 1st quarter revenue difference increased from 2008 to 2009. So logically, 4th to 1st quarter revenue difference will also increase in 2010.
However, the chart predicts earnings of $1.30 ($0.50 + $0.80), slightly lower than the $1.36 estimate. 4th to 1st quarter earnings difference remained about $0.80 in 2008 and 2009, so we can assume it will remain about $0.80 in 2010.
The chart below shows calculations for the growth from prior years.
|
Revenue Difference – Year-over-year |
EPS Difference – Year-over-year |
||||
|
|
2009 to 2010 |
2008 to 2009 |
|
2009 to 2010 |
2008 to 2009 |
|
1st Qrt |
1.574 (22%) |
-1.500 (-17%) |
1st Qrt |
0.70 (130%) |
-0.77 (-59%) |
|
2nd Qrt |
1.992 (28%) |
-2.191 (-24%) |
2nd Qrt |
0.56 (92%) |
-0.5 (-45%) |
|
3rd Qrt |
0.911 (15%) |
-1.561 (-20%) |
3rd Qrt |
-0.05 (-11%) |
-0.11 (-19%) |
|
4th Qrt |
0.928 (14%) |
0.744 (12%) |
4th Qrt |
0.06 (14%) |
0.72 (257%) |
This chart predicts they should blow away revenue estimates. The $9.22 billion 2011 1st quarter estimate is only $376 million higher than the $8.844 billion made in the 1st quarter of 2010. If the 2009 to 2010 1st quarter revenue difference was $1.574 billion, the year-over-year revenue increase must fall by about $1.2 billion. Yes, the recent acquisition will likely hurt revenues, but by this much?
The chart gives a low estimate of $1.30 ($1.24 + $0.06) and a high estimate of $1.94 ($1.24 + $0.70). The low estimate is below the $1.36 estimate, but the high estimate is far higher. Assuming that the acquisition shaves $0.30-$0.45, the earnings will still be higher than $1.36 when using the high estimate of $1.94.
Thus, it seems that the company will beat estimates and may get an upgrade before they announce, boosting the stock price. The chance of them missing estimates is small.
Lastly, let’s see what the charts are telling us.
Surprisingly, the Stochastic %K and %D showed a bearish cross above the overbought (80) line. When the %K and %D crosses above the overbought (80) line, that is a sell signal. And this happened before back in May (red line) despite a low W%R.
As the W%R moves toward the oversold (80) line, this is a sign of increasing bullishness. However, a buy signal is not given until the W%R is below the oversold (20) line. The purple lines show four instances when the W%R approached, and crossed in the first three, the oversold (80) line. In all of the instances, the stock moved higher. The W%R is at exactly the same point as the last purple line, meaning the stock may trend higher.
The MFI (Money Flow Index) and RSI (Relative Strength Index) just crossed under the overbought (80 for MFI and 70 for RSI) lines. A falling MFI is not necessarily a bearish signal but means that negative money flow (money flowing out of the stock) is greater than positive money flow (money flowing into a stock.
Thus, the technicals say that the stock will likely fall to the support line before trending higher. Using the slopes (-$0.18 and $0.07), the stock could fall to $51.12 over the next 16 days before rising to $61.45 in 47 days after that.
In summary, prepare for a short-term pullback before a long-term upward trend.
= = = = = = = = = = = = = = =
3. Exelixis (EXEL) – Time To Excel
Exelixis (EXEL, $11.82, up $0.25) reported earnings last week and we wanted to go over their numbers real quick. They beat on earnings by 24%, reporting a loss of $0.16 a share versus analysts’ estimates for a loss of $0.21 a share. They also beat on revenue by 5%, reporting $166.4 million versus estimates for $137.4 million. As a result, the stock surged 10% after the announcement and put in a strong week. The narrower loss was cheered by investors who worried that the company will run out of money before its first drug could reach approval.
Is the stock still worth investing? We say yes, but not until after a pullback to $10.
Earlier this month, the company received very positive results on treatment on its prostate cancer drug XL 184. Phase III results are expected in a few months and speculation is that they will file for approval in the 2nd half of this year.
Moreover, there are a number of companies interested in Exelixis as takeover speculation continues to make water-cooler talk. Drug giant Bristol-Myers Squibb (BMY, $25.49, up $0.09) had already previously backed out of an earlier partnership with the company on drug XL 184 but came back. And XL 184 is not the only drug in Exelixis’ pipeline. With many of Big Pharma companies, including Pfizer (PFE, $18.86, down $0.04) loosing patents in major blockbuster drugs, promising small biotech’s look ripe for picking. If Bristol-Myers doesn’t buy this company, someone will. Prostate cancer is a multibillion dollar business and the drug could be seen as a replacement for any blockbuster drug coming off of patent.
Insiders and institutions are buying. Should you?
The graphs below show that the stock has been marching higher in a narrow trading range. It is currently at resistance and is likely to fall back to support, before continuing higher. The technicals support this assumption. The MFI (Money Flow Index), RSI (Relative Strength Index), Stochastic %K and %D, and W%R are all near or in overbought territory. The MFI is near the overbought (80) line, a sell signal. The RSI is above the overbought (70) line, a sell signal. The %K and %D just crossed above the overbought (80) line. When the %K and %D crosses above the overbought (80) line, this is a sell signal. The W%R is above the overbought (20) line, a sell signal.
The three lines (two orange and one purple) show how the price reacted to similar situations. The two orange lines show that the price fell after the signal, but only until the price fell back to support. After that, it resumed its uptrend. However, the price did not fall after the purple line. This could be explained because the price had not reached resistance. In the other cases, it did.
Therefore, since the current price is at resistance, it will likely fall to support before rising. Further, we can speculate that it will fall $0.08 per day meaning it will reach about $10 in 25 days. From there, shares could zoom back up to $14 in the 25 days afterwards.
= = = = = = = = = = = = = = =
4. Earnings
The companies in BOLD, we are looking at as possible trades and we may list call or put options on them in our Daily Newsletter. If they become official recommendations, we sent out Trade Alerts or include them in our 9am and 1pm updates that come out during the week. The first set of companies report before the bell that day, the second set after the market closes. (Quotes are as of Friday’s close, 2/25/11).
MONDAY
Allied Nevada Gold Corp (ANV, $30.00, up $0.77), Franklin Electric (FELE, $42.74, up $1.16), JinkoSolar Holdings (JKS, $29.24, up $1.22), Mobile Mini (MINI, $21.88, up $0.64), Weingarten Realty Investors (WRI, $25.72, up $0.55)
A123 Systems (AONE, $9.54, down $0.12), DigitalGlobal (DGI, $32.50, up $2.57), Isis Pharmaceuticals (ISIS, $9.08, up $0.15), Salix Pharmaceuticals (SLXP, $33.49, up $1.88), Sotheby Holdings (BID, $48.26, up $1.33), Tower Group (TWGP, $27.21, up $0.53), Vivus (VVUS, $7.64, up $0.06)
TUESDAY
AutoZone (AZO, $255.39, up $2.14), Bank of Montreal (BMO, $63.00, up $0.23), Boyd Gaming (BYD, $10.73, up $0.43), Domino’s Pizza (DPZ, $16.79, up $0.35), ReneSola (SOL, $11.54, down $0.28), Tech Data (TECD, $49.80, up $0.39)
B&G Foods (BGS, $14.37, up $0.48), Cal Dive International (DVR, $6.67, up $0.20), Churchill Downs (CHDN, $40.89, up $0.44), Dendron (DNDN, $33.66, up $0.61), Evergreen Solar (ESLR, $2.10, Flat), Hovnanian Enterprises (HOV, $4.14, up $0.12), MBIA (MBI, $11.30, up $0.44), Shanda Games Limited (GAME, $6.08, $0.39), Sina (SINA, $81.48, up $3.48)
WEDNESDAY
BJ’s Wholesale Club (BJ, $48.54, up $0.60), Costco Wholesale (COST, $73.57, up $0.59), Joy Global (JOYG, $93.93, up $0.53), Staples (SPLS, $20.94, up $0.23)
Chiquita Brands International (CQB, $16.45 up $0.54), Coldwater Creek (CWTR, $2.96, up $0.04), Copart (CPRT, $41.19, up $0.68), Eagle Bulk Shipping (EGLE, $4.13, down $0.03), Famous Dave’s of America (DAVE, $10.31, up $0.21), Foot Locker (FL, $19.29, up $0.26), NACCO Industries (NC, $122.20, up $4.79), Redwood Trust (RWT, $16.44, up $0.03)
THURSDAY
Big Lots (BIG, $40.71, up $0.93), Crown Media Holdings (CRWN, $2.39, up $0.10), Del Monte Foods (DLM, $18.94, up $0.02), Genesis Energy L.P. (GEL, $29.31, up $1.15), H.J. Heinz (HNZ, $50.00, up $0.43), Kroger (KR, $22.86, down $0.11), Safeguard Scientifics (SFE, $21.08, up $2.50), Toronto-Dominion Bank (TD, $82.65, up $2.13)
Cooper Companies (COO, $61.56, up $2.09), Jazz Pharmaceuticals (JAZZ, $24.48, up $0.60), Marvell Technology Group (MRVL, $18.92, up $0.90), Novell (NOVL, $5.91, down $0.01), Spreadtrum Communications (SPRD, $21.27, up $0.83), PETsMART (PETM, $41.17, up $1.54), Silver Wheaton (SLW, $40.63, up $2.01)
FRIDAY
Assisted Living Concepts (ALC, $35.32, up $2.22), Madison Square Garden (MSG, $27.41, down $0.05), Royal Bank of Canada (RY, $57.88, up $0.38)
MDC Partners (MDCA, $17.41, up $0.16)
= = = = = = = = = = = = = = =
5. Weekly Wrap Covered Call Portfolio Update (Closing prices as of 2/25/11)
Spreadtrum Communications (SPRD, $21.27, up $0.83)
March 24 call (SPRD110319C00024000, $0.55, up $0.25)
Entry Price: $23.45 (2/7/11) sold March 24 calls @ $0.95
Exit Target: $30
Return: -5%
Stop Target: None
Action: Shares opened at $23.43 on 2/7/11 and the calls could have been sold for 95 cents. This lowered the cost basis to $22.48. The company reports earnings this week. We are expecting a good quarter.
DryShips (DRYS, $4.90, up $0.03)
January 2012 7.50 call (DRYS120121C00007500, $0.37, flat)
Entry Price: $5.25 (1/03/11) sold January 2012 7.50 call @ $0.65
Exit Target: $8
Return: 7%
Stop Target: None
Action: DryShips opened at $5.37 on 1/3/11 and shares were at $5.25 shortly after the bell. The options opened at 69 cents so you should have gotten 65-70 cents for selling them. This lowered the cost basis to $4.60.
If shares are over $7.50 by January 2012, you would be “called away” and the trade would make nearly 70%. We like the risk/reward factor these options offer.
Seattle Genetics (SGEN, $15.16, up $0.30)
March 17.50 calls (SGEN110319C00017500, $0.10, flat)
Entry Price: $15.50 (12/27/10) sold March 17.50 calls @ $0.90
Exit Target: $20
Return: 4%
Stop Target: None
Action: Seattle Genetics opened at $15.80 and shares were at $15.50 at 10am on 12/27/10. The March 17.50 call option could have been sold for 90 cents. This lowered the cost basis to $14.60. We like this company a lot going forward and their pipeline. Continue to hold.
Dendreon (DNDN, $33.66, up $0.61)
Entry Price: $41.96 (9/13/10) sold October 45 call @ $1.30, (11/11/10) sold December call @$1.75, (12/20/10) sold February 39 call @ $1.50
Exit Target: $45
Return: -10%
Stop Target: None
Action: Dendreon reports earnings on Tuesday so we could get a pop higher. Shares have been in a slight downtrend but the momentum could come back on a good earnings announcement. We are waiting for shares to test $37-$38 again before selling another call.
Dendreon opened at $41.96 and you could have sold the October 45 call option for $1.30 on 9/13/10. This lowered the cost basis to $40.66.
On 11/11/10 we sold the December 40 call option for $1.75 which lowered our cost basis to $38.91.
On 12/20/10 we sold the February 39 call option for $1.50 which lowered our cost basis to $37.41.
We will have to wait for a bounce back above $35 to sell another near-term option. Shares have been in a downtrend but solid support is at $32 and then $30. If shares get this low they would be a “compelling” buy.
= = = = = = = = = = = = = = =
6. Week Ahead
This will be a big week for economic news.
On Monday, Personal Income and Personal Spending are due out before the bell. PCE Prices will also be released and covers these categories; durables, nondurables and services. After the opening bell we get the Chicago PMI Report and an update on housing with Pending Home Sales expecting to show a decline of 1.5%.
Tuesday will be quiet before the open, but shortly after the open we get Construction Spending and the ISM Index numbers. Later in the day, Auto Sales and Truck Sales will be released.
For Wednesday, the market will digest the MBA Mortgage Index, the Challenger Job Cuts number, and the ADP Employment Change report. We will also get an update on Crude Inventories as well as the Fed’s Beige Book.
On Thursday, Initial Claims and Continuing Claims are due out before the bell with the ISM Services numbers coming shortly after the open.
Friday will be big as the market gets the latest Nonfarm Payrolls figures and the Unemployment Rate. Also out are the Average Workweek and Hourly Earnings numbers as well as Factory Orders 30 minutes after the open.
As we prepare for a possible down week, there could be some pluses from earnings and economic news could come in better-than-expected for some of the bigger reports. If earnings and economic news are weaker-than-expected, the market could also start to fall into a trading range if our next set of downside targets comes into play. In any event, a lot of this week’s market action will follow the price of oil.
]]>



